Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b <scp>OCARINA</scp> I studyScott D. Newsome, Robert A Bermel, Oscar Bortolami et al.|Annals of Clinical and Translational Neurology|2024Cited by 3